Application Submitted to the EMA to expand the therapeutic indication for IMBRUVICA® (ibrutinib) to include treatment of Waldenström’s macroglobulinemia
- EMEA Innovative Medicine
- IMBRUVICA® (ibrutinib) Treatment Expanded Throughout the EMA
IMBRUVICA® (ibrutinib) Treatment Expanded Throughout the EMA
- X (Twitter)
Copy link